Freshfields is advising Roivant Sciences Ltd. (Nasdaq: ROIV) on the sale of Telavant, a Roivant company owned by Roivant and Pfizer, to Roche for $7.1 billion in cash and a near-term milestone payment of $150 million in cash. More details on the transaction can be found here.

The Freshfields team is led by M&A partners Damien Zoubek and Jenny Hochenberg, senior associates Tomas Rua and Arash Ardalan, and associates Joyce Yeo, Connor Smith and Clara Barnosky. Partner Adam Golden, counsel Jeff Jay and associates Sora Park and Joshua Samuel advised on life sciences matters; partner Lori Goodman, senior associate Andrew Herman and associate Lina Zhu advised on executive compensation and employee benefits matters; partners Joe Soltis and Paul Davison and associates Emily Szasz, Brendan Counihan and Hannah Golden advised on tax matters; and partners Jamillia Ferris, Meghan Rissmiller and Jenny Leahy advised on antitrust matters.